Jazz Pharmaceuticals announced progress in its Phase 3 ACTION trial for Modeyso (dordaviprone), a treatment for rare H3 K27M-mutant diffuse glioma brain cancer. The trial is testing overall survival benefits in patients post-radiotherapy, with interim results expected in early 2027. The company also initiated a Phase 2 trial for JZP3507 targeting recurrent meningioma, showing promising preclinical anti-cancer activity. These developments highlight Jazz's commitment to innovative therapies for aggressive brain cancers.
Jazz Pharmaceuticals' neuro-oncology clinical research progress is presented here with Pluang's Health sector data for context. For readers following Health stocks, as of Nov 02, 2026 20:02 WIB, 87 of 150 priced US Health-sector stocks rose while 43 fell. Among notable movers, NTRA (Natera Inc.) traded at USD 423.00 with a 2.13% increase, contrasting with CGC (Canopy Growth Corp) at USD 0.67 and a 2.10% rise, and CRL (Charles River Laboratories Intl.) at USD 367.14 with a 2.07% gain. Typical hold times ranged from 18 to 40 days on Pluang.
Maurizio Mian, known as the pioneer of influencer culture, has launched a new micro-drama series called 'The Experiment.' The show features popular social media personalities living in luxury while exploring whether happiness can be measured and incr...
The global wealth management software market, valued at $6.28 billion in 2025, is projected to reach $18.77 billion by 2033, growing at a 14.7% CAGR. Growth is fueled by rising adoption of AI, automation, and digital advisory tools that enhance workf...
The global bio-based construction polymer market, valued at $18.2 billion in 2025, is projected to grow to $35 billion by 2033 at an 8.3% CAGR. Growth is fueled by rising demand for sustainable building materials that reduce greenhouse gas emissions ...
Annual Over-the-Air (OTA) software updates for software-defined vehicles (SDVs) are projected to reach over 2 billion globally by 2035, up from 546 million in 2025, driven by rising SDV sales and advanced vehicle software platforms. Level 3 and above...
Fram Wind Solutions AS, a joint venture partly owned by BW Offshore, secured a NOK 1.94 billion grant from Enova to develop a floating offshore wind project featuring two 18.5 MW turbines, the largest globally, with a combined capacity of 37 MW. The ...
